NCO 700 sulfate
NCO-700 sulfate is a dual cathepsin B and calcium-activated neutral protease (CANP) inhibitor with IC50 values of 0.8 and 46 μM, respectively. NCO-700 sulfate reduces the degradation of myocardial fibrin by inhibiting protease activity. NCO-700 sulfate also has inhibitory effects on hormone-independent tumor cells, such as prostate cancer cells, and induces apoptosis. NCO-700 sulfate can be used to study myocardial ischemia and refractory hormone-independent tumors.
For research use only. We do not sell to patients.
- CAS No.: 84579-82-8
- Formula: C26H41N3O12S
- Molecular Weight:619.68
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Cathepsin Isoforms
More
Biological Activity
Description
In Vitro
NCO-700 (7 days) sulfate inhibits HS-578T, PC-3, DU-145, MCF-7, LNCaP and T47D cells proliferation with IC50s of 7.5, 10, 11.5, 72 and >100 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
NCO-700 (10-100 mg/kg, i.p., once daily for 5 days) sulfate demonstrates significant anti-tumor activity in xenograft models of prostate cancer and breast cancer in mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:
-
Dosage:20 and 40 mg/kg (total dose)
-
Administration:Intraperitoneal injection (i.p.), 4 administrations of medication
-
Result:Reduce the infarcted area by 11.5% and 22.3% at 20 and 40 mg/kg in rabbit model.
Significantly inhibited the degradation of myofibrillar proteins induced by ischemia in dog model.
-
Animal Model:Xenograft models of prostate cancer and breast cancer established in Balb/C mice[2]
-
Dosage:10, 20 and 40 mg/kg (prostate cancer) and 10, 50 and 100 mg/kg (breast cancer)
-
Administration:Intraperitoneal injection (i.p.), once daily for 5 days
-
Result:Significantly slowed down the growth rate of the tumor.
Induced cell apoptosis in cancer cells removed from animals.
Chemical Information
-
CAS No. 84579-82-8
-
Molecular Weight 619.68
-
Formula C26H41N3O12S
-
SMILES
S(=O)(=O)(O)O.C(N[C@H](C(=O)N1CCN(CC2=C(OC)C(OC)=C(OC)C=C2)CC1)CC(C)C)(=O)[C@H]3[C@H](C(OCC)=O)O3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
[1]. Toyo-oka T, et al. Reduction of experimentally produced acute myocardial infarction size by a new synthetic inhibitor, NCO-700, against calcium-activated neutral protease. Jpn Heart J. 1982 Sep;23(5):829-34. [Content Brief]
[2]. Eilon GF, et al. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents. Cancer Chemother Pharmacol. 2000;45(3):183-91. [Content Brief]
[3]. Sashida H, Abiko Y. Inhibition with NCO-700, a protease inhibitor, of degradation of cardiac myofibrillar proteins during ischemia in dogs. Biochem Pharmacol. 1985 Nov 1;34(21):3875-80. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)